Ana Aparicio, MD

Peer-Reviewed Articles

1. Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist 27(11):940-951, 2022. e-Pub 2022. PMID: 35983951.
2. Li H, Wang Y, Lin K, Venkadakrishnan VB, Bakht M, Shi W, Meng C, Zhang J, Tremble K, Liang X, Song JH, Feng X, Van V, Deng P, Burks JK, Aparicio A, Keyomarsi K, Chen J, Lu Y, Beltran H, Zhao D. CHD1 promotes sensitivity to Aurora kinase inhibitors by suppressing interaction of AURKA with its coactivator TPX2. Cancer Res 82(17):3088-3101, 2022. e-Pub 2022. PMID: 35771632.
3. Zhang B, Stewart CA, Wang Q, Cardnell RJ, Rocha P, Fujimoto J, Solis Soto LM, Wang R, Novegil V, Ansell P, He L, Fernandez L, Jendrisak A, Gilbertson C, Schonhoft JD, Byun J, Jones J, Anderson AKL, Aparicio A, Tran H, Negrao MV, Zhang J, Wang WL, Wistuba II, Wang J, Wenstrup R, Byers LA, Gay CM. Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. Br J Cancer 127(3):569-576, 2022. e-Pub 2022. PMID: 35440668.
4. Chai S, Ruiz-Velasco C, Naghdloo A, Pore M, Singh M, Matsumoto N, Kolatkar A, Xu L, Shishido S, Aparicio A, Zurita AJ, Hicks J, Kuhn P. Identification of epithelial and mesenchymal circulating tumor cells in clonal lineage of an aggressive prostate cancer case. NPJ Precis Oncol 6(1):41, 2022. e-Pub 2022. PMID: 35729213.
5. Ranasinghe WKB, Troncoso P, Surasi DS, Ibarra Rovira JJ, Bhosale P, Szklaruk J, Kokorovic A, Wang X, Elsheshtawi M, Zhang M, Aparicio A, Chapin BF, Bathala TK. Defining Diagnostic Criteria for Prostatic Ductal Adenocarcinoma at Multiparametric MRI. Radiology 303(1):204732, 2022. e-Pub 2022. PMID: 35076303.
6. Yadav D, Hwang H, Qiao W, Upadhyay R, Chapin BF, Tang C, Aparicio A, Lopez-Olivo MA, Kang SK, Macapinlac HA, Bathala TK, Surasi DS. 18F-fluciclovine versus PSMA PET Imaging in Primary Tumor Detection during Initial Staging of High-Risk Prostate Cancer: A Systematic Review and Meta-Analysis. Radiol Imaging Cancer 4(2):e210091, 2022. PMID: 35212559.
7. Chai S, Matsumoto N, Storgard R, Peng CC, Aparicio A, Ormseth B, Rappard K, Cunningham K, Kolatkar A, Nevarez R, Tu KH, Hsu CJ, Malihi P, Corn P, Zurita A, Hicks J, Kuhn P, Ruiz-Velasco C. Platelet-Coated Circulating Tumor Cells Are a Predictive Biomarker in Patients with Metastatic Castrate-Resistant Prostate Cancer. Mol Cancer Res 19(12):2036-2045, 2021. e-Pub 2021. PMID: 34462330.
8. Spetsieris N, Boukovala M, Alafis I, Davis J, Zurita A, Wang X, Tu SM, Chapin BF, Aparicio A, Corn P, Wang J, Subudhi SK, Araujo J, Papadopoulos J, Pruitt L, Weldon JA, Logothetis CJ, Efstathiou E. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. Eur J Cancer 157:259-267, 2021. e-Pub 2021. PMID: 34536949.
9. Subudhi SK, Siddiqui BA, Aparicio AM, Yadav SS, Basu S, Chen H, Jindal S, Tidwell RSS, Varma A, Logothetis CJ, Allison JP, Corn PG, Sharma P. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer 9(10), 2021. PMID: 34663638.
10. Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis C. Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open 8(8):e2122998, 2021. e-Pub 2021. PMID: 34459906.
11. Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable Responses in Patients with Genitourinary Cancers Following Immune Checkpoint Therapy Rechallenge after Moderate to Severe Immune-Related Adverse Events. J Immunother Cancer 9(7), 2021. PMID: 34326169.
12. Sarker D, Dawson NA, Aparicio AM, Dorff TB, Pantuck AJ, Vaishampayan UN, Henson L, Vasist L, Roy-Ghanta S, Gorczyca M, York W, Ganji G, Tolson J, de Bono JS. A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. e-Pub 2021. PMID: 34281912.
13. Quinn DI, Tsao-Wei DD, Twardowski P, Aparicio AM, Frankel P, Chatta G, Wright JJ, Groshen SG, Khoo S, Lenz HJ, Lara PN, Gandara DR, Newman E. Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879. Invest New Drugs 39(3):812-820, 2021. e-Pub 2021. PMID: 33409898.
14. Oke O, Ranasinghe W, Tang C, Shaaban S, Xiao L, Reichard CA, Anscher MS, Chapin BF, Aparicio A. Impact of Definitive Local Therapy in Men with Primary Small Cell Prostate Carcinoma. Eur Urol. e-Pub 2021. PMID: 33824032.
15. Ranasinghe W, Shapiro DD, Zhang M, Bathala T, Navone N, Thompson TC, Broom B, Aparicio A, Tu SM, Tang C, Davis JW, Pisters L, Chapin BF. Optimizing the diagnosis and management of ductal prostate cancer. Nat Rev Urol. e-Pub 2021. PMID: 33824525.
16. Gerdtsson AS, Setayesh SM, Malihi PD, Ruiz C, Carlsson A, Nevarez R, Matsumoto N, Gerdtsson E, Zurita A, Logothetis C, Corn PG, Aparicio AM, Hicks J, Kuhn P. Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate Cancer. Cancers (Basel) 13(5), 2021. e-Pub 2021. PMID: 33801459.
17. Palanisamy N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, Labanca E, Manyam GC, Ravoori MK, Kundra V, Araujo JC, Efstathiou E, Pisters LL, Wan X, Wang X, Vazquez ES, Aparicio AM, Carskadon SL, Tomlins SA, Kunju LP, Chinnaiyan AM, Broom BM, Logothetis CJ, Troncoso P, Navone NM. The MD Anderson prostate cancer patient-derived xenograft series (MDA PCa PDX) captures the molecular landscape of prostate cancer and facilitates marker-driven therapy development. Clin Cancer Res 26(18):4933-4946, 2020. e-Pub 2020. PMID: 32576626.
18. Malihi PD, Graf RP, Rodriguez A, Ramesh N, Lee J, Sutton R, Jiles R, Ruiz Velasco C, Sei E, Kolatkar A, Logothetis C, Navin NE, Corn P, Aparicio AM, Dittamore R, Hicks J, Kuhn P, Zurita AJ. Single-cell circulating tumor cell analysis reveals genomic instability as a distinctive feature of aggressive prostate cancer. Clin Cancer Res 26(15):4143-4153, 2020. e-Pub 2020. PMID: 32341031.
19. Sang K, Murphy WA, Aparicio A, Subudhi SK. RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer. Journal of Immunotherapy and Precision Oncology 3(3), 2020. e-Pub 2020.
20. Ranasinghe WKB, Brooks NA, Elsheshtawi MA, Davis JW, Bathala TK, Tang C, Troncoso P, Aparicio A, Tu SM, Pisters LL, Chapin BF. Patterns of metastases of prostatic ductal adenocarcinoma. Cancer. e-Pub 2020. PMID: 32453443.
21. Spetsieris N, Boukovala M, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wang X, Wen S, Efstathiou E. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. e-Pub 2020. PMID: 32675015.
22. Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, Reuben A, Aparicio A, Corn PG, Chapin BF, Pisters LL, Troncoso P, Tidwell RS, Thall P, Wu CJ, Zhang J, Logothetis CL, Futreal A, Allison JP, Sharma P. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med 12(537), 2020. PMID: 32238575.
23. Abu-Gheida I, Bathala TK, Maldonado JA, Khan M, Anscher MS, Frank SJ, Choi S, Nguyen QN, Hoffman KE, McGuire SE, Kim M, Kuban DA, Aparicio A, Chapin BF, Tang C. Increased frequency of Mesorectal and Perirectal LN involvement in T4 Prostate Cancers. Int J Radiat Oncol Biol Phys. e-Pub 2020. PMID: 32353391.
24. Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, Titus MA, Panaretakis T, Gallick GE, Efstathiou E, Troncoso P, Logothetis C. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. Clin Cancer Res 26(5):990-999, 2020. e-Pub 2020. PMID: 31941830.
25. Bagley AF, Anscher MS, Choi S, Frank SJ, Hoffman KE, Kuban DA, McGuire SE, Nguyen QN, Chapin B, Aparicio A, Pezzi TA, Smith GL, Smith BD, Hess K, Tang C. Association of Sociodemographic and Health-Related Factors with Receipt of Nondefinitive Therapy Among Younger Men with High-Risk Prostate Cancer. JAMA Netw Open 3(3):e201255, 2020. e-Pub 2020. PMID: 32191331.
26. Boukovala M, Spetsieris N, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wen S, Efstathiou E. A candidate androgen signaling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer 127:67-75. e-Pub 2020. PMID: 31986451.
27. Tzelepi V, Logotheti S, Efstathiou E, Troncoso P, Aparicio A, Sakellakis M, Hoang A, Perimenis P, Melachrinou M, Logothetis C, Zolota V. Epigenetics and prostate cancer: defining the timing of DNA methyltransferase deregulation during prostate cancer progression. Pathology. e-Pub 2019. PMID: 31864524.
28. Jiao S, Subudhi SK, Aparicio A, Ge Z, Guan B, Miura Y, Sharma P.. Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. Cell 179:1177-1190, 2019.
29. Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, Li-Ning-Tapia E, Tu SM, Subudhi SK, Wang J, Wang X, Efstathiou E, Thompson TC, Troncoso P, Navin N, Logothetis CJ, Aparicio AM. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol 20(10):1432-1443, 2019. e-Pub 2019. PMID: 31515154.
30. Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, Xiong L, Trojer P, Aparicio A, Subudhi SK, Allison JP, Zhao H, Sharma P. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest 128(9):3813-3818, 2018. e-Pub 2018. PMID: 29905573.
31. Reichard CA, Gregg JR, Achim MF, Aparicio AM, Pettaway CA, Pisters LL, Ward JF, Davis JW, Chapin BF. Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes. Eur Urol. e-Pub 2018. PMID: 29656854.
32. Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, Park S, Azad AK, Cao X, Kim J, Corn PG, Logothetis CJ, Aparicio AM, Chinnaiyan AM, Navone N, Troncoso P, Thompson TC. Targeting the MYCN-PARP-DNA Damage Response Pathway inNeuroendocrine Prostate Cancer. Clin Cancer Res 24(3):696-707, 2018. e-Pub 2017. PMID: 29138344.
33. Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol 80(3):583-589, 2017. e-Pub 2017. PMID: 28730293.
34. Ganeshan D, Aparicio AM, Morani A, Kundra V. Pattern and Distribution of Distant Metastases in Anaplastic Prostate Carcinoma: A Single-Institute Experience With 101 Patients. AJR Am J Roentgenol 209(2):327-332, 2017. e-Pub 2017. PMID: 28590819.
35. Karanika S, Karantanos T, Li L, Wang J, Park S, Yang G, Zuo X, Song JH, Maity SN, Manyam GC, Broom B, Aparicio AM, Gallick GE, Troncoso P, Corn PG, Navone N, Zhang W, Li S, Thompson TC. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Cell Rep 18(8):1970-1981, 2017. PMID: 28228262.
36. Ferrara F, Staquicini DI, Driessen WHP, D'Angelo S, Dobroff AS, Barry M, Lomo LC, Staquicini FI, Cardó-Vila M, Soghomonyan S, Alauddin MM, Flores LG, Arap MA, Lauer RC, Mathew P, Efstathiou E, Aparicio AM, Troncoso P, Navone NM, Logothetis CJ, Marchiò S, Gelovani JG, Sidman RL, Pasqualini R, Arap W. Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer. Proc Natl Acad Sci U S A 113(45):12786-12791, 2016. e-Pub 2016. PMID: 27791181.
37. Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Allison JP, Sharma P. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A 113(42):11919-11924, 2016. e-Pub 2016. PMID: 27698113.
38. Aparicio AM, Shen L, Tapia EL, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncoso P, Corn P, Thompson TC, Broom B, Baggerly K, Maity SN, Logothetis CJ. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res 22(6):1520-30, 2016. e-Pub 2015. PMID: 26546618.
39. Kleb B, Estécio MR, Zhang J, Tzelepi V, Chung W, Jelinek J, Navone NM, Tahir S, Marquez VE, Issa JP, Maity S, Aparicio A. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas. Epigenetics 11(3):0, 2016. e-Pub 2016. PMID: 26890396.
40. Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, Aparicio A, Hoang AG, Gaur S, Thorpe L, Maity SN, Bar Eli M, Czerniak BA, Shao Y, Alauddin M, Lin SH, Logothetis CJ, Gallick GE. Integrating murine and clinical trials with cabozantinib to understand roles of MET and VEGFR-2 as targets for growth inhibition of prostate cancer. Clin Cancer Res 22(1):107-21, 2016. e-Pub 2015. PMID: 26272062.
41. Gao J, He Q, Subudhi S, Aparicio A, Zurita-Saavedra A, Lee DH, Jimenez C, Suarez-Almazor M, Sharma P. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene 34(43):5411-7, 2015. e-Pub 2015. PMID: 25659583.
42. Campbell MT, Millikan RE, Altinmakas E, Xiao L, Wen SJ, Siefker-Radtke AO, Aparicio A, Corn PG, Tannir NM. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma. Clin Genitourin Cancer 13(3):218-24, 2015. e-Pub 2014. PMID: 25465491.
43. Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol 67(1):53-60, 2015. e-Pub 2014. PMID: 24882673.
44. Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer 1(121(1)):69-76, 2015. e-Pub 2014. PMID: 25155428.
45. Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Li Ning Tapia EM, Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. (Research highlights on this article published in Nature Reviews Urology on September 23, 2014 and Cancer Discovery on September 25, 2014). Sci Transl Med 6(252):252ra122, 2014. PMID: 25186177.
46. Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karhiou E, Maity SN, Aparicio AM, Li Ning Tapia EManika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstat, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC. Targeting poly(ADP-Ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal 7(326):ra47, 2014. e-Pub 2014. PMID: 24847116.
47. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 19(13):3621-30, 2013. e-Pub 2013. PMID: 23649003.
48. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 62(6):1013-9, 2012. e-Pub 2012. PMID: 22771265.
49. Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Koumakpayi IH, Saad F, Luo D, Bismar TA, Aparicio A, Troncoso P, Navone N, Zhang W. Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. Am J Pathol 180(3):895-903, 2012. e-Pub 2012. PMID: 22245216.
50. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM. Modeling lethal prostate cancer variant with small cell carcinoma features. Clin Cancer Res 18(3):666-77, 2012. e-Pub 2011. PMID: 22156612.
51. Bhatia S, Moon J, Margolin KA, Weber JS, Lao CD, Othus M, Aparicio AM, Ribas A, Sondak VK. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. PLoS One 7(11):e48787, 2012. e-Pub 2012. PMID: 23226204.
52. Sonpavde G, Aparicio AM, Zhan F, North B, Delaune R, Garbo LE, Rousey SR, Weinstein RE, Xiao L, Boehm KA, Asmar L, Fleming MT, Galsky MD, Berry WR, Von Hoff DD. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaive castration-resistant prostate cancer. Urol Oncol 29(6):682-9, 2011. e-Pub 2009. PMID: 19959380.
53. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: Morphological, immunohistochemical and gene expression profiles. Prostate 71(8):846-56, 2011. e-Pub 2010. PMID: 21456067.
54. Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. Phase I clinical trial of pegylated liposomal doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol 34(1):27-31, 2011. e-Pub 2010. PMID: 20142723.
55. Guo CC, Dancer JY, Wang Y, Aparicio A, Navone NM, Troncoso P, Czerniak BA. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol 42(1):11-7, 2011. e-Pub 2010. PMID: 21040948.
56. Jonasch E, Corn P, Pagliaro LC, Warneke CL, Johnson MM, Tamboli P, Ng C, Aparicio A, Ashe RG, Wright JJ, Tannir NM. Upfront randomized phase II trial of sorafenib versus sorafenib and low-dose interferon alpha in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 116(1):57-65, 2010. PMID: 19862815.
57. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-81, 2009. e-Pub 2009. PMID: 19636008.
58. Gorlov IP, Byun J, Gorlova OY, Aparicio AM, Efstathiou E, Logothetis CJ. Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. BMC Med Genomics 4(2):48, 2009. e-Pub 2009. PMID: 19653896.
59. Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, Aparicio A , Guo CC, Kuban DA, Johnson MM, Pisters LL. Ductal adenocarcinoma of the prostate:clinical features and implications after local therapy. Cancer 115(13):2872-80, 2009. PMID: 19402048.
60. Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D, Yoo C, Tannir N, Horne E, Groshen S, Jones P, Yang A, Issa JP. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics 4(3):176-84, 2009. e-Pub 2009. PMID: 19421002.
61. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Wong C, Aparicio AM, Gandara DR, Somlo G. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 14(21):7138-42, 2008. PMID: 18981013.
62. Egger G, Aparicio AM , Escobar SG, Jones PA. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment. Cancer Res 67(1):346-53, 2007. PMID: 17210717.
63. Aparicio A, Eads C, Leong L, Laird PW, Newman N, Weber JS. Phase I trial of continuous infusion 5-Aza-2'-deoxyctidine (DAC). Cancer Chemother Pharmacol 51(3):231-39, 2003. PMID: 12655442.
64. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12(2):220-29, 1998. PMID: 9519785.

Invited Articles

1. Berchuck JE, Viscuse PV, Beltran H, Aparicio A. Clinical considerations for the management of androgen indifferent prostate cancer. Prostate Cancer Prostatic Dis. e-Pub 2021. PMID: 33568748.
2. Laudato S, Aparicio A, Giancotti FG. Clonal Evolution and Epithelial Plasticity in the Emergence of AR-Independent Prostate Carcinoma. Trends Cancer 5(7):440-455, 2019. e-Pub 2019. PMID: 31311658.
3. Logothetis CJ, Aparicio A, Koinis F, Corn PG, Efstathiou E. Prostate Cancer: Quo Vadis?. Eur Urol. e-Pub 2019. PMID: 31300238.
4. Meeks JJ, Goldkorn A, Aparicio AM, McConkey DJ. Development of a translational medicine protocol for an NCTN genitourinary clinical trial: Critical steps, common pitfalls and a basic guide to translational clinical research. Urol Oncol 37(5):313-317, 2019. e-Pub 2018. PMID: 30115512.
5. Soundararajan R, Paranjape AN, Maity S, Aparicio A, Mani SA. EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers. Biochim Biophys Acta Rev Cancer 1870(2):229-238, 2018. e-Pub 2018. PMID: 29981816.
6. Metcalfe MJ, Smaldone MC, Lin DW, Aparicio AM, Chapin BF. Role of radical prostatectomy in metastatic prostate cancer: A review. Urol Oncol 35(4):125-134, 2017. e-Pub 2017. PMID: 28190749.
7. Basourakos SP, Li L, Aparicio AM, Corn PG, Kim J, Thompson TC. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. Curr Med Chem 24(15):1586-1606, 2017. e-Pub 2016. PMID: 27978798.
8. Aparicio A, Tzelepi V. Neuroendocrine (small-cell) carcinomas: why they teach us essential lessons about prostate cancer. Oncology (Williston Park) 28(10):831-8, 2014. e-Pub 2014. PMID: 25323607.
9. Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, Logothetis C, Rubin MA. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 20(11):2846-50, 2014. e-Pub 2014. PMID: 24727321.
10. Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov 3(8):849-61, 2013. e-Pub 2013. PMID: 23811619.
11. Aparicio A, Den RB, Knudsen KE. Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. Nat Rev Urol 8(10):562-8, 2011. e-Pub 2011. PMID: 21811228.
12. Alva AS, Hahn NM, Aparicio AM, Singal R, Yellapragada S, Sonpavde G. Hypomethylating agents for urologic cancers. Future Oncol 7(3)(3):447-63, 2011. PMID: 21417907.
13. Albany C, Alva AS, Aparicio AM, Singal R, Yellapragada S, Sonpavde G, Hahn NM. Epigenetics in prostate cancer. Prostate Cancer 2011:580318, 2011. e-Pub 2011. PMID: 22191037.
14. Aparicio A. The potential of histone deacetylase inhibitors in lung cancer. Clin Lung Cancer 7(5)(5):309-12, 2006. PMID: 16640801.
15. Aparicio AM, Elkhouiery AB, Quinn DI. The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy. Urol Clin North Am 32(2):217-30, 2005. PMID: 15862619.
16. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429(6990):457-63, 2004. PMID: 15164071.
17. Aparicio A, Chamberlain MC. Neoplastic meningitis. Curr Neurol Neurosci Rep 2(3):225-35, 2002. PMID: 11937001.
18. Aparicio A, Weber JS. Review of the clinical experience with 5-Azacytidine and 5-Aza-2'-deoxycytidine in solid tumors. Curr Opin Investig Drugs 3(4):627-33, 2002. PMID: 12090735.
19. Weber JS, Aparicio A. Novel immunologic approaches to the management of malignant melanoma. Curr Opin Oncol 13(2):124-28, 2001. PMID: 11224710.

Other Articles

1. Soundararajan R, Aparicio AM, Logothetis CJ, Mani SA, Maity SN Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers. Front Oncol 8:69, 2018. PMID: 29600194.
2. Chapin BF, McGuire SE, Aparicio AM Local Therapy in Metastic Prostate Cancer: Does an Integrated Approach Improve Clinical Outcomes?. 2015 Genitourinary Cancers Symposium Daily News(2), 2015.
3. Aparicio AM Prostate Cancer: Clinical practitioner perspective. Endocrine News, 2011.
4. Sonpavde G, Aparicio A, Guttierez I, Boehm KA, Hutson TE, Berry WR, Asmar L, von Hoff DD Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy. Clin Genitourin Cancer 5(7):457-9, 2007. PMID: 18272030.

Editorials

1. Logothetis C, Aparicio A, Thompson TC. ER stress in prostate cancer: A therapeutically exploitable vulnerability?. Sci Transl Med 10(439), 2018. PMID: 29720450.
2. Logothetis CJ, Aparicio AM. Is It Time to Re-Examine Prostate Cancer Treatment Paradigm by Targeting the Interaction Between the Prostate and Metastases?. J Clin Oncol 34(24):2810-1, 2016. PMID: 27432923.
3. Chapin BF, McGuire SE, Aparicio A. Is treatment of the primary tumor in metastatic prostate cancer justified?. Eur Urol 65(6):1067-8, 2014. PMID: 24411278.
4. Goldkorn A, Aparicio AM, Quinn DI. Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore. Ann Oncol 24(7):1717-20, 2013. PMID: 23798673.
5. Aparicio A, Logothetis CJ, Maity SN. Understanding the lethal variant of prostate cancer: Power of examining extremes. Cancer Discov 1(6):466-8, 2011. PMID: 22586648.

Abstracts

1. Viscuse P, Tidwell R, Liu J, Guo S, Vundavilli H, Zhang M, Subudhi S, Zurita A, Corn P, Tu S, Araujo J, Wang J, Efstathiou E, Wang J, Pilié P, Troncoso P, Zhang J, Wang W, Logothetis C, Aparicio A. DynAMo: A dynamic allocation modular sequential trial of approved and promising therapies in men with metastatic CRPC. 2022 ASCO, 2022.
2. Viscuse P, Zhang M, Liu J, Slack Tidwell R, Subudhi SK, Zurita AJ, Corn PG, Tu SM, Araujo JC, Wang J, Eftathiou E, Wang J, Pilie PG, Troncoso P, Zhang J, Logothetis C, Aparicio A. Linking the Aggressive Variant Prostate Cancer (AVPC) Molecular Signature (-ms) to Androgen Indifference in a Prospective Clinical Trial. Journal of Clinical Oncology 38(6 suppl):156-156, 2020. e-Pub 2020.
3. Efstathiou E, Boukovala M, Spetsieris N, Wen S, Hoang A, Weldon JA, Tidwell R, Davis JW, Chapin BF, Corn PG, Subudhi SK, Aparicio A, Pettaway CA, Pister LL, Papadopoulos JN, Adibi M, Wang J, Zurita AJ, Logothetis C, Troncoso P.. Neoadjuvant Apalutamide (APA) plus Leuprolide (LHRHa) With or Without Abiraterone (AA) in Localized High-risk Prostate Cancer (LHRPC). 2020 ASCO Virtual Scientific Program, 2020.
4. Zhang M, Aparicio A , Wang X, Chapin B, Troncoso P. Aggressive Variant Prostate Cancer in Men with Hormone Naïve, de novo Metastatic Prostate Cancer (M1PC). United States & Canadian Academy of Pathology's 109th Annual Meeting, 2019. e-Pub 2019.
5. Subudhi S, Aparicio A, Zurita A, Doger B, Kelly WK, Peer A, Rathkopf D, Karsh L, Tryon JJ, Kothrari N, Zhao X, Zhu E, Ricce D, Tran N, DeBono J. A phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (NCT03431350). 2019 ASCO, 2019.
6. Aparicio A, Zhang M, Ramesh N, Wang Xuemei, Corn P, Zurita A, Davis J, Pettaway C, Adibi M, Mcguire S, Tu SM, Wang J, Subudhi S, Elesheshtai M, Efstathiou E, Logothetis C, Navin N, Troncoso P, Chapin BF. Aggressive variant prostate cancer (AVPC) molecular signature in castration-sensitive, de novo metastatic prostate cancer (M1PCa). 2019 ASCO, 2019.
7. Zurita A, Tidwell RS, Troncoso P, Chapin BF, Harris D, Pisters LL, Araujo JC, Pettaway CA, Aparicio A, Tu SM, Papadopoulos JN, Wang J, Logothetis C, Pagliaro LC, Davis JW. Randomized phase II trial of presurgical androgen deprivation therapy (ADT) with or without axitinib in prostate cancer (PCa) presenting with lymph node (LN) metastasis. 2019 ASCO, 2019.
8. Chapin BF, Wang X, Zhang M, Corn P, Zurita AJ, Elsheshtawi MA, Davis JW, Pettaway CA, Adibi M, Gleave M, Cooperberg MR, Smaldone MC, Mcguire SE, Tu SM, Wang J, Subudhi SK, Efstathiou E, Logothetis C, Troncoso P, Aparicio A. Complex biologic heterogeneity of de novo hormone naive metastatic prostate cancer (HNPCa): Comparison of early progressors and prolonged responders to initial systemic treatment. 2019 ASCO, 2019.
9. Siddiqui B, Durand J, Gao J, Wang J, Aparicio A, Campbell MT, Siefker-Radtke AO, Tannir NM, Corn PG, Msaouel P, Shah AY, Zurita AJ, Tu SM, Suarez-Almazor ME, Sudhakar T, Logothetis C, Sharma P, Subudhi SK. Clinical and immunological analyses of immune checkpoint inhibitor-associated neuromuscular (NM) toxicities. 2019 ASCO, 2019.
10. Efstathiou E, Wang X, Zurita A, Tu SM, Aparicio A, Wang J, Corn PG, Subudhi SK, Araujo JC, Reece LK, Pruitt L, Vanalstine ML, Logothetis C. A randomized study of finite abiraterone acetate (AA) plus leuprolide (LHRHa) versus LHRHa in biochemically recurrent non metastatic hormone naive prostate cancer (M0HNPC). 2018 ASCO, 2018.
11. Oke O, Tang C, Shaaban S, Xiao L, Reichard CA, Chapin BF, Anscher MS, Aparicio A. Impact of definitive local therapy (LT) in men with primary small cell (or poorly differentiated neuroendocrine) prostate carcinomas (pSCPC). 2018 ASCO, 2018.
12. Reichard CA, Gregg J, Achim MF, Aparicio A, Pisters LL, Ward JF, Davis JW, Chapin BF. Radical prostatectomy in metastatic castration-resistant prostate cancer: Feasibility, safety, and quality of life outcomes. Genitourinary Cancers Symposium, 2018.
13. Corn PG, Subudhi SK, Araujo JC, Vardake I, Aparicio A, Tu SM, Pagliaro LC, Zurita AJ, Logothetis C, Panaretakis T. Molecular profiling of liquid biopsies from patients (pts) with bone metastatic castration-resistant prostate cancer (BM-CRPC) treated with radium-223 (RA-223) to reveal differential enrichment for markers that correlate with overall survival (OS). Genitourinary Cancers Symposium, 2018.
14. A Aparicio, L. Xiao, E. L. Tapia, A. Hoang, N. Ramesh, W. Wu, H. Chancoco, E. I. Heath, E. Efstathiou, T. C. Thompson, P. Troncoso, B. M. Broom, A. J. Zurita, N. Navin, C. Logothetis, P. G. Corn. The aggressive variant prostate carcinoma (AVPC) molecular signature (-MS) and platinum-sensitivity in castration resistant prostate cancer (CRPC). 2017 ASCO(abstr 5013), 2017.
15. S. K. Subudhi, A. Aparicio, P. Troncoso, J. Zhang, C. Gumbs, C. Wu, J. Gao, L. M. Vence, J. M. Blando, P. G. Corn, J. C. Araujo, A. J. Zurita, I. N. Prokhorova, M. Van Alstine, C. Logothetis, A. Futreal, J. P. Allison, P. Sharma. Linking tumor mutational load to clinical responses to ipilimumab (IPI) in men with advanced prostate cancer (PCa). 2017 ASCO(abstr 5065), 2017.
16. Corn PG, Zurita AJ, Subudhi SK, Tu SM, Aparicio A, Araujo JC, Kim J, Wang J, Efstathiou E, Pagliaro L, Logothetis CJ. Cabozantinib plus androgen deprivation therapy in patients with androgen-dependent metastatic prostate cancer. GU ASCO(abstr 179608), 2017.
17. Paul Gettys Corn, Elsa Li Ning Tapia, Lianchun Xiao, Elisabeth I. Heath, Haidee Chancoco, Anh Hoang, Eleni Efstathiou, Timothy C. Thompson, Patricia Troncoso, Christopher Logothetis, Ana Aparicio. Confirmatory analysis to determine associations between platinum-sensitivity, molecular signature of combined tumor suppressor defects and aggressive variant prostate carcinomas (AVPC). J Clin Oncol 34(suppl; abstr 5020), 2016.
18. Sumit Kumar Subudhi, Ana Aparicio, Patricia Troncoso, Jianhua Zhang, Curtis Gumbs, Chang-jiun Wu, Luis M Vence, Christopher Logothetis, Andrew Futreal, James Patrick Allison, Padmanee Sharma. A feasibility study to determine T cell responses to neoantigens following treatment with ipilimumab in men with metastatic castration-resistant prostate carcinoma (mCRPC). J Clin Oncol 34(suppl; abstr e14506), 2016.
19. Bruno C. Odisio, Jared Allen Christensen, Sumit Kumar Subudhi, Steven Huang, Sanjay Gupta, Kamran Ahrar, Rahul Sheth, Joe Ensor, Ana Aparicio. Image guided thermal ablation of prostate cancer metastases to the liver. J Clin Onco 34(suppl; abstr e16515), 2016.
20. Chapin BF, McGuire S, Wang X, Sharma P, Troncosco P, Davis J, Navai N, Subudhi S, Zurita A, Araujo J, Pettaway C, Matin S, Pisters L, Ward J, Tu SM, Wang J, Ott L, Logothetis CJ, Aparicio Ana. A prospective, multicenter, randomized phase II trial of best systemic therapy (BST) or BST plus definitive treatment (surgery or radiation) of the primary tumor in metastatic prostate cancer. J Clin Oncol 33(suppl; abstr TPS5075), 2015.
21. Quinn DI, Ruel N, Twardowski PW, Groshen SG, Dorff TB, Pal SK, Stadler WM, Aparicio A, Lara PN, Newman, EM. Eribulin in advanced urothelial cancer (AUC) patients (pts): A california cancer consortium trial (NCI/CTEP 7435). J Clin Oncol 33(suppl; abstr 4504), 2015.
22. Aparicio A, Shen L, Li Ning Tapia E, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncoso P, Corn PG, Thompson TC, Broom BM, Baggerly KA, Logothetis CJ, Maity SN. Molecular characterization of clinically defined aggressive variant prostate cancer (AVPCa) in prospectively collected tissues and corresponding patient derived xenografts (PDX). J Clin Oncol 33(suppl; abstr 5055), 2015.
23. Corn, PG, Tu SM, Zurita AJ, Subudhi SK, Araujo JC, Kim J, Jonasch E, Pagliaro LC, Siefker-Radtke AO, Wang J, Wang X, Heath EI, Logothetis C, Aparicio A.. A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 33(suppl; abstr 5010), 2015.
24. Aparicio A, Shen L, Li-Ning Tapia E, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncoso P, Broom B, Baggerly K, Logothetis CJ, Maity S. A comprehensive molecular characterization of aggressive variant prostate cancer (PC). J Clin Oncol 33(suppl 7, abstr 149), 2015.
25. Maity SN, Guanglin Wu G, Lu JF, Hoang A, Landesman Y, McCauley D, Carlson R, Rashal T, Shacham S, Broom BM, Baggerly KA, Aparicio A, Efstathiou E, Araujo JC, Logothetis CJ. Effect of selinexor (KPT-330), a novel oral selective inhibitor of nuclear export (SINE), on tumor suppressors and cell cycle proteins in prostate cancer cells and regression of castration-resistant patient-derived xenograft tumor growth. J Clin Oncol 33(suppl 7, abstr 277), 2015.
26. Bilen MA, Hess KR, Aparicio A, Kim J, Zurita AJ, Pagliaro LC, Araujo JC, Corn PG, Atkinson BJ, Tannir NM, Sharma P, Lin SH, Logothetis C, Tu SM. Sipuleucel-T cellular immunotherapy: Clinical predictors of survival in patients with castration-resistant prostate cancer (CRPC). J Clin Oncol 32(suppl; abstr e16046), 2014.
27. Corn PG, Tu SM, Zurita AJ, Araujo JC, Pagliaro LC, Logothetis CJ, Aparicio A. A randomized phase I/II study to examine the contribution of carboplatin to cabazitaxel for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) with and without anaplastic features. J Clin Oncol 32(suppl 4 ; abstr 148), 2014.
28. Aparicio A, Maity S, Wang X, Hoang AG, Efstathiou E, Troncoso P, Logothetis CJ,. A molecular characterization of the anaplastic prostate carcinomas. 2013 AACR Annual Conference, 2013.
29. Aparicio A, Gallichotte E, Cheng H, Yoo SY, Maity S, Logothetis CJ, Tewari M,. Circulating micro-RNAs can detect adaptive response to therapy and aggressive subset of prostate cancer. 2013 AACR Annual Conference, 2013.
30. Kleb BN, Estecio M, Wu G, Lu JF, Logothetis CJ, Maity S, Aparicio A. Mechanism of androgen receptor (AR) silencing in small cell prostate carcinoma. 2013 AACR Annual Conference 73(8 suppl; abst 2986), 2013.
31. Corn PG, Varkaris A, Li Ning Tapia EM, Araujo JC, Aparicio A, Tu SM, Zurita AJ, Efstathiou E, Qiao W, Wen S, Gallick GE, Logothetis C. Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib. J Clin Oncol 31, 2013.
32. Quinn DI, Hamid O, Tsao-Wei D, Hu J, Pinski J, Schuckerman A, Daneshmand S, Groshen S, Raghaven D, Korn C, Massopust K, Ketchens C, Aparicio AM, Dorff TB. Gemcitabine, oxaliplatin, and paclitaxel (GOT) on a 2-weekly schedule in patients (PTS) with refractory germ cell carcinoma: A phase II study conducted at the University of Southern California. Ann Oncol 23(9):ix258-ix293, 2012.
33. Kleb B, Estecio M, Zhang J, Tzelepi V, Chung, W, Maity S, Logothetis C, Troncoso P, Navone N, Jelinek J, Liang S, Issa J, Aparicio A. The DNA methylome of castration-resistant prostate cancer. Oral Presentation. 2012 AACR Annual Conference, Chicago, IL. Cancer Research 72(8 suppl), 2012.
34. Aparicio A, Sun, J, Ng Tang D, Arap W, Araujo J, Corn P, Tannir N, Wang X, Radtke A, Sharma P,. A phase II study of ipilumimab plus androgen deprivation therapy in castration-sensitive prostate carcinoma. Cancer Research 72(6), 2012.
35. Aparicio A, Harzstark L, Lin E, Corn P, Araujo J, Tu S, Pagliaro L, Millikan R, Arap W, Kim J, Ryan C, Zurita A, Tannir N, Lin A, Small J, Mathew P, Jones D, Troncoso P, Thall P, Logothetis C. Characterization of the anaplastic prostate carcinomas: A prospective two-stage phase II trial of frontline carboplatin and docetaxel (CD) and salvage etoposide and cisplatin (EP). J Clin Oncol 29, 2011.
36. Tzeelpi V, Maity S, Zhang J, Liang S, Lu JF, Anh H, Kleb B, Efstathiou E, Navone N, Troncoso P, Logothetis C, Aparicio A. Molecular profiling of prostate cancer xenografts and human specimens reveals overexpression of UBE2C/UBCH10 and activation of aurora kinases in poorly differentiated neuroendocrine carcinoma of the prostate. Cancer Research 71(8):10.1158/1538-7445.AM2011-36, 2011.
37. Tzelepi V, Maity S, Zhang J, Karlou M, Liang S, Hoang A, Lu J, Kleb B, Efstathiou E, Navone N, Aparicio A, Troncoso P. Differential expression of UBE2C and ASCL1 in neuroendocrine carcinoma and adenocarcinoma of the prostate in xenograft models and human samples. USCAP Annual Meeting, San Antonio, TX, 2011.
38. Efstathiou E, Tu S, Aparicio A, Hoang A, Troncoso P, Smith L, Chieffo N, Molina A, Logothetis C,. Use of "intracrine androgen signaling signature" to predict benefit from abiraterone acetate(AA) in patients with castrate-resistant prostate cancer (CRPC). J Clin Oncol 28(15s), 2010.
39. Jonasch E, Wood G, Matin S, Tamboli K, Do L, Pagliaro C, Aparicio AM, Araujo JC, Tannir NM.. Presurgical bevacizumab in patients with metastatic clear cell renal cell carcinoma: A phase II study. J Clin Oncol 26(15S):275s, 2008.
40. Aparicio AM, Lin AM, Araujo JC, Logothetis CJ, Kim J, Pagliaro LC, Tu S, Guo C, Jones D, Thall P, Mathew P.. Use of clinical features to select a chemotherapy-responsive variant of aggressive prostate cancer (PC). J Clin Oncol 26(15S):271s, 2008.
41. Aparicio A, North B, Yang J, Jelinek J, Guo C, Logothetis C, Navone N, Issa JP. DNA methylation profiles can discriminate prostate cancer phenotypes. Gordon Research Conference, Ventura, CA, 2008.
42. Sonpavde G, Aparicio AM, Delaune R, Garbo LE, Rousey SR, Weinstein RE, Williams A, Zhan F, Boehm KA, Asmar L, Von Hoff DD.. Azacitidine for castration-resistant prostate cancer progressing on combined androgen blockade. J Clin Oncol 26, 2008.
43. Tannir NM, Zurita AJ, Heymach JV, Tran HT, Pagliaro LC, Corn P, Aparicio AM, Ashe R, Wright JJ, Jonasch E.. A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis. J Clin Oncol 26(15S), 2008.
44. Cheung EM, Quinn DI, Tsao-Wei DD, Groshen SG, Aparicio AM, Twardowski P, Shatta GS, Lara Jr. PN, Gandara DR. Phase II study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy--California Cancer Consortium/University of Pittsburgh NCI/CTEP-sponsored trial. J Clin Oncol 26(15S), 2008.
45. Luu TH, Leong L, Morgan R, McNamara M, Lim D, Portnow J, Frankel P, Aparicio A, Chew H, Gandara DR, Somlo G. Vorinostat (suberoylanilide hydroxamic acid) as salvage therapy in metastatic breast cancer (MBC): A California Cancer Consortium phase II study. J Clin Oncol 25(18S), 2007.
46. Ramalingam S, Parise RA, Egorin MJ, Argiris A, Stoller R, Beattie l, Aparicio A, Newman EM, Zwiebel J, Belani CP. Phase I study of vorinostat, a histone deacetylase (HDAC) inhibitor, in combination with carboplatin (Cb) and paclitaxel (P) for patients with advanced solid malignancies (NCI # 6922). J Clin Oncol 24(18S), 2006.
47. Dorff TB, Rupani R, Wei DT, Groshen S, Pinski J, Raghavan D, Quinn D, Aparicio A. POMB-ACE therapy for patients with international germ cell cancer collaborative group (IGCCCG) poor risk germ cell tumors (GCT): The USC experience. J Clin Oncol 24(18S), 2006.
48. Egger G, Aparicio A , Escobar S, Jones PA. Effects of combinatiorial treatment of T24 cells with 5-aza-2' deoxycytidine and 4-phenylbutyric acid. AACR 96th Annual Meeting Proceedings Vol 46, 2005. e-Pub 2005.
49. Barske L, Bollati V, Yang AS, Aparicio AM. A comparison of bisulfite-based DNA methylation assays for the measurement of DNA methylation changes induced by decitabine. AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics:Discovery, Biology, and Clinical Applications, 2005.
50. Aparicio A, Iqbal S, Yang D, Groshen S, Park A, Garcia A, Lenz HJ. Pilot trial of 5-Fu/oxaliplatin (CIFOX) for patients with metastatic colorectal cancer who progressed on 5-FU/LV/CPT-11 (lFL). J Clin Oncol, (Post-Meeting Edition) 14S((July 15 Supplement)), 2004.

Book Chapters

1. Tagawa ST, Aparicio A, Robinson B, Sing-Batra J, Golden E. Uncommon Cancers of the Prostate. In: Textbook of Uncommon Cancers. 5th, 2017.
2. Logothetis CJ, Kim J, Davis JW, Chapin BF, Kuban DA, Efstathiou E, Aparicio A. 98 Neoplasm of the Prostate. In: Holland-Frei Cancer Medicine. 9th. Wiley-Blackwell: Hoboken, New Jersey, 2017.
3. Logothetis CJ, Troncoso P, Kim J, Davis JW, Kuban DA, Mathew P, Aparicio A. Neoplasm of the Prostate. In: Cancer Medicine. 8th. People Medical Publishing House-USA: Shelton, CONN, 1228-1254, 2010.
4. Aparicio A, Sharma P, Millikan RE. Experimental systemic therapy of metastatic urothelial cancer. In: UpToDate, Basow, DS(Ed), UpToDate, Waltham, MA, 2009.

Letters to the Editor

1. Aparicio A, Thall P, Logothetis C. Radiotherapy for metastatic prostate cancer. Lancet 394: 829-830, 2019.
2. Aparicio A, Logothetis CJ. Reply to J.B. Aragon-Ching and D. Dalela et al. J Clin Oncol 35: 917-918, 2017.